Phio Pharmaceuticals Corp. Earnings Per Share Diluted

• Phio Pharmaceuticals Corp. showed an increase of +80.6% in Earnings Per Share Diluted from 2023 to 2024.
• This data is from Phio Pharmaceuticals Corp.'s annual report (Form 10-K), filed with the SEC on March 31, 2025.
• XBRL data for this metric is available from 2021 to 2024 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Quarterly values from 10-Q filings: Q1 2021: $0.32 (loss) per share | Q2 2021: $0.20 (loss) per share | Q3 2021: $0.28 (loss) per share | Q1 2022: $2.34 (loss) per share | Q2 2022: $2.22 (loss) per share | Q3 2022: $3.14 (loss) per share | Q1 2023: $3.15 (loss) per share | Q2 2023: $13.27 (loss) per share | Q3 2023: $10.25 (loss) per share | Q1 2024: $0.47 (loss) per share | Q2 2024: $3.62 (loss) per share | Q3 2024: $1.54 (loss) per share | Q1 2025: $0.41 (loss) per share | Q2 2025: $0.45 (loss) per share.
• Over the full 4 years of available data (2021 to 2024), Phio Pharmaceuticals Corp.'s Earnings Per Share Diluted has grown by 27.0%.
• Historical annual values: Fiscal year 2024: $9.08 (loss) per share | Fiscal year 2023: $46.76 (loss) per share | Fiscal year 2022: $10.10 (loss) per share | Fiscal year 2021: $12.43 (loss) per share.
• Data sourced from SEC EDGAR public filings as of August 7, 2026.

Last verified: August 7, 2026